PM8002 + FOLFIRI

**PM8002 + FOLFIRI** is an investigational combination therapy being studied for the treatment of neuroendocrine neoplasms (NEN), especially as a second-line therapy for patients who have failed first-line platinum-based chemotherapy. PM8002 is a bispecific antibody targeting both PD-L1 and VEGF, harnessing both immune checkpoint inhibition and anti-angiogenic effects. FOLFIRI is a well-established chemotherapy regimen composed of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. FOLFIRI’s primary mechanism is cytotoxic, disrupting DNA synthesis and replication in cancer cells. The combination of PM8002 and FOLFIRI is administered intravenously every two weeks and is designed to provide synergistic anti-tumor activity—combining immune system activation, anti-angiogenesis, and direct chemotherapeutic cytotoxicity[1][2][3][7][9].